{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:34:06Z","timestamp":1793810046129,"version":"4.6.1"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Antipsychotics, such as quetiapine, are frequently prescribed to people with dementia to address behavioral symptoms but can also cause harm in this population.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine whether warning letters to high prescribers of quetiapine can successfully reduce its use among patients with dementia and to investigate the impacts on patients\u2019 health outcomes.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This is a secondary analysis of a randomized clinical trial of overprescribing letters that began in April 2015 and included the highest-volume primary care physician (PCP) prescribers of quetiapine in original Medicare. Outcomes of patients with dementia were analyzed in repeated 90-day cross-sections through December 2018. Analyses were conducted from September 2021 to February 2024.<\/jats:p><\/jats:sec>Interventions<\/jats:title>PCPs were randomized to a placebo letter or 3 overprescribing warning letters stating that their prescribing of quetiapine was high and under review by Medicare.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome of this analysis was patients\u2019 total quetiapine use in days per 90-day period (the original trial primary outcome was total quetiapine prescribing by study PCPs). Prespecified secondary outcomes included measures of cognitive function and behavioral symptoms from nursing home assessments, indicators of depression from screening questionnaires in assessments and diagnoses in claims, metabolic diagnoses derived from assessments and claims, indicators of use of the hospital and other health care services, and death. Outcomes were analyzed separately for patients living in nursing homes and in the community.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 5055 study PCPs, 2528 were randomized to the placebo letter, and 2527 were randomized to the 3 warning letters. A total of 84\u202f881 patients with dementia living in nursing homes and 261\u202f288 community-dwelling patients with dementia were attributed to these PCPs. There were 92\u202f874 baseline patients (mean [SD] age, 81.5 [10.5] years; 64\u202f242 female [69.2%]). The intervention reduced quetiapine use among both nursing home patients (adjusted difference, \u20130.7 days; 95% CI, \u22121.3 to \u22120.1 days; P<\/jats:italic>\u2009=\u2009.02) and community-dwelling patients (adjusted difference, \u22121.5 days; 95% CI, \u22121.8 to \u22121.1 days; P<\/jats:italic>\u2009&amp;lt;\u2009.001). There were no detected adverse effects on cognitive function (cognitive function scale adjusted difference, 0.01; 95% CI, \u22120.01 to 0.03; P<\/jats:italic>\u2009=\u2009.19), behavioral symptoms (agitated or reactive behavior adjusted difference, \u22120.2%; 95% CI \u22121.2% to 0.8% percentage points; P<\/jats:italic>\u2009=\u2009.72), depression, metabolic diagnoses, or more severe outcomes, including hospitalization and death.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This study found that overprescribing warning letters to PCPs safely reduced quetiapine prescribing to their patients with dementia. This intervention and others like it may be useful for future efforts to promote guideline-concordant care.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT05172687<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.7604","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T15:33:24Z","timestamp":1714059204000},"page":"e247604","source":"Crossref","is-referenced-by-count":9,"title":["Physician Antipsychotic Overprescribing Letters and Cognitive, Behavioral, and Physical Health Outcomes Among People With Dementia"],"prefix":"10.1001","volume":"7","author":[{"given":"Michelle","family":"Harnisch","sequence":"first","affiliation":[{"name":"PhD Economics Programme, Department of Economics, London School of Economics and Political Science, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Barnett","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Coussens","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Mailman School of Public Health, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kali S.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Center for Equity in Aging, Johns Hopkins University School of Nursing, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Olfson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Department of Epidemiology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiros","family":"Berhane","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sacarny","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Mailman School of Public Health, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"issue":"7","key":"zoi240287r4","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1377\/hlthaff.2016.1439","article-title":"CMS strategies to reduce antipsychotic drug use in nursing home patients with dementia show some progress.","volume":"36","author":"Lucas","year":"2017","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"zoi240287r5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/2040622316658463","article-title":"Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses.","volume":"7","author":"Tampi","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"key":"zoi240287r6","doi-asserted-by":"publisher","first-page":"h369","DOI":"10.1136\/bmj.h369","article-title":"Assessment and management of behavioral and psychological symptoms of dementia.","volume":"350","author":"Kales","year":"2015","journal-title":"BMJ"},{"issue":"9","key":"zoi240287r7","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1176\/appi.ajp.2012.12030342","article-title":"Atypical antipsychotic use in patients with dementia: managing safety concerns.","volume":"169","author":"Steinberg","year":"2012","journal-title":"Am J Psychiatry"},{"issue":"5","key":"zoi240287r8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1176\/appi.ajp.2008.08081218","article-title":"Metabolic changes associated with second-generation antipsychotic use in Alzheimer\u2019s disease patients: the CATIE-AD study.","volume":"166","author":"Zheng","year":"2009","journal-title":"Am J Psychiatry"},{"issue":"5","key":"zoi240287r9","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"zoi240287r10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1176\/appi.ajp.2011.08121844","article-title":"Cognitive effects of atypical antipsychotic medications in patients with Alzheimer\u2019s disease: outcomes from CATIE-AD.","volume":"168","author":"Vigen","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"7","key":"zoi240287r12","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.v71.7","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults.","volume":"71","author":"The American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"zoi240287r13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1176\/appi.ajp.2015.173501","article-title":"The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia.","volume":"173","author":"Reus","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"3","key":"zoi240287r16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1056\/NEJM199207163270306","article-title":"A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes.","volume":"327","author":"Avorn","year":"1992","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi240287r17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1017\/S003329170700147X","article-title":"The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards\u2014a cluster randomized controlled trial.","volume":"38","author":"Thompson","year":"2008","journal-title":"Psychol Med"},{"issue":"4","key":"zoi240287r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3630","article-title":"Association of the US Food and Drug Administration antipsychotic drug boxed warning with medication use and health outcomes in elderly patients with dementia.","volume":"3","author":"Rubino","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi240287r19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jamda.2018.05.002","article-title":"Antipsychotic deprescription for older adults in long-term care: the HALT Study.","volume":"19","author":"Brodaty","year":"2018","journal-title":"J Am Med Dir Assoc"},{"issue":"11","key":"zoi240287r20","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.jamda.2022.06.029","article-title":"Association between long-term care facility staffing levels and antipsychotic use in US long-term care facilities.","volume":"23","author":"Chappell","year":"2022","journal-title":"J Am Med Dir Assoc"},{"issue":"10","key":"zoi240287r21","doi-asserted-by":"publisher","first-page":"897.e1","DOI":"10.1016\/j.jamda.2017.06.032","article-title":"Influences on decision-making regarding antipsychotic prescribing in nursing home residents with dementia: a systematic review and synthesis of qualitative evidence.","volume":"18","author":"Walsh","year":"2017","journal-title":"J Am Med Dir Assoc"},{"issue":"11","key":"zoi240287r23","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.jamda.2020.05.039","article-title":"Trends in antipsychotic and mood stabilizer prescribing in long-term care in the U.S.: 2011-2014.","volume":"21","author":"Gerlach","year":"2020","journal-title":"J Am Med Dir Assoc"},{"issue":"10","key":"zoi240287r24","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamapsychiatry.2018.1867","article-title":"Effect of peer comparison letters for high-volume primary care prescribers of quetiapine in older and disabled adults: a randomized clinical trial.","volume":"75","author":"Sacarny","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"zoi240287r26","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1056\/NEJMsa063979","article-title":"Care patterns in Medicare and their implications for pay for performance.","volume":"356","author":"Pham","year":"2007","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi240287r27","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1056\/NEJMsa1414929","article-title":"Performance differences in year 1 of pioneer accountable care organizations.","volume":"372","author":"McWilliams","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi240287r28","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1097\/MLR.0000000000000334","article-title":"The Minimum Data Set 3.0 cognitive function scale.","volume":"55","author":"Thomas","year":"2017","journal-title":"Med Care"},{"issue":"12","key":"zoi240287r29","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jamda.2019.08.030","article-title":"The Minimum Data Set agitated and reactive behavior scale: measuring behaviors in nursing home residents with dementia.","volume":"20","author":"McCreedy","year":"2019","journal-title":"J Am Med Dir Assoc"},{"issue":"5","key":"zoi240287r30","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/gps.v34.5","article-title":"Measurement validity of the Patient-Health Questionnaire-9 in US nursing home residents.","volume":"34","author":"B\u00e9langer","year":"2019","journal-title":"Int J Geriatr Psychiatry"},{"key":"zoi240287r31","doi-asserted-by":"publisher","first-page":"l1476","DOI":"10.1136\/bmj.l1476","article-title":"Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis.","volume":"365","author":"Levis","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"zoi240287r32","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/j.jamda.2021.05.010","article-title":"Uncontrolled pain and risk for depression and behavioral symptoms in residents with dementia.","volume":"22","author":"Jenny Wei","year":"2021","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"zoi240287r33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1745-6215-15-139","article-title":"The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies.","volume":"15","author":"Kahan","year":"2014","journal-title":"Trials"},{"issue":"1","key":"zoi240287r34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/qje\/qjac038","article-title":"When should you adjust standard errors for clustering?","volume":"138","author":"Abadie","year":"2022","journal-title":"Q J Econ"},{"issue":"1","key":"zoi240287r35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12883-019-1260-3","article-title":"Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis.","volume":"19","author":"Aigbogun","year":"2019","journal-title":"BMC Neurol"},{"issue":"10029","key":"zoi240287r36","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S0140-6736(16)00215-4","article-title":"Provision of social norm feedback to high prescribers of antibiotics in general practice: a pragmatic national randomised controlled trial.","volume":"387","author":"Hallsworth","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"zoi240287r37","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1377\/hlthaff.2015.1025","article-title":"Medicare letters to curb overprescribing of controlled substances had no detectable effect on providers.","volume":"35","author":"Sacarny","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"zoi240287r38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/MLR.0b013e31818457ce","article-title":"Predictors of nursing home admission for persons with dementia.","volume":"47","author":"Gaugler","year":"2009","journal-title":"Med Care"},{"issue":"2","key":"zoi240287r39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/milq.2004.82.issue-2","article-title":"Driven to tiers: socioeconomic and racial disparities in the quality of nursing home care.","volume":"82","author":"Mor","year":"2004","journal-title":"Milbank Q"},{"issue":"2","key":"zoi240287r40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1177\/08982643211043319","article-title":"Quality of care and outcomes among a diverse group of long-term care residents with Alzheimer\u2019s disease and related dementias.","volume":"34","author":"Rivera-Hernandez","year":"2022","journal-title":"J Aging Health"},{"issue":"5","key":"zoi240287r41","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1377\/hlthaff.26.5.1448","article-title":"Separate and unequal: racial segregation and disparities in quality across U.S. nursing homes.","volume":"26","author":"Smith","year":"2007","journal-title":"Health Aff (Millwood)"},{"issue":"10","key":"zoi240287r42","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1080\/13607863.2020.1758921","article-title":"Agreement of Minimum Data Set 3.0 depression and behavioral symptoms with clinical diagnosis in a nursing home.","volume":"25","author":"Wei","year":"2021","journal-title":"Aging Ment Health"},{"issue":"10","key":"zoi240287r43","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1176\/ps.62.10.pss6210_1159","article-title":"Medicare beneficiaries with depression: comparing diagnoses in claims data with the results of screening.","volume":"62","author":"Noyes","year":"2011","journal-title":"Psychiatr Serv"},{"key":"zoi240287r1","unstructured":"Centers for Medicare & Medicaid Services. National partnership to improve dementia care in nursing homes: antipsychotic medication use data report. April 2022. Accessed April 12, 2023. https:\/\/www.cms.gov\/files\/document\/antipsychotic-medication-use-data-report-2021q4-updated-07292022.pdf"},{"key":"zoi240287r2","unstructured":"Centers for Medicare & Medicaid Services. Antipsychotic use in Part D enrollees with dementia. November 16, 2015. Accessed March 11, 2024. https:\/\/www.cms.gov\/Medicare\/Prescription-Drug-Coverage\/PrescriptionDrugCovGenIn\/Downloads\/Antipsychotic-Use-in-Part-D-Enrollees-with-Dementia-v12092015.pdf"},{"key":"zoi240287r3","unstructured":"Government Accountability Office. Antipsychotic drug use: HHS has initiatives to reduce use among older adults in nursing homes, but should expand efforts to other settings. January 2015. Accessed March 11, 2024. https:\/\/www.gao.gov\/assets\/gao-15-211.pdf"},{"key":"zoi240287r11","unstructured":"US Food and Drug Administration. Information for healthcare professionals: conventional antipsychotics. June 16, 2008. Accessed March 13, 2023. https:\/\/wayback.archive-it.org\/7993\/20170722190727\/https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124830.htm"},{"key":"zoi240287r14","unstructured":"Centers for Medicare & Medicaid Services. National partnership to improve dementia care in nursing homes: antipsychotic medication use data report. April 2019. Accessed December 10, 2019. https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Downloads\/Antipsychotic-Medication-Use-Data-Report.pdf"},{"key":"zoi240287r15","unstructured":"Centers for Medicare & Medicaid Services. State operations manual: appendix PP\u2014guidance to surveyors for long term care facilities. 2023. Accessed March 11, 2024. https:\/\/www.cms.gov\/Regulations-and-Guidance\/Guidance\/Manuals\/downloads\/som107ap_pp_guidelines_ltcf.pdf"},{"key":"zoi240287r22","unstructured":"Centers for Medicare & Medicaid Services. Medicare Part D spending by drug. 2023. Accessed June 2, 2023. https:\/\/data.cms.gov\/jsonapi\/node\/dataset\/63b6ee35-4593-4525-a9cc-4d39cd1e9132"},{"key":"zoi240287r25","unstructured":"Sacarny? A, Harnisch? M, Barnett? ML. The effect of de-prescribing antipsychotics on health and quality of life for people with dementia. January 12, 2022. Accessed May 23, 2023. https:\/\/osf.io\/eh47k\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2818095\/harnisch_2024_oi_240287_1713456869.90024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T15:33:28Z","timestamp":1714059208000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2818095"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.7604","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]}}}